Here are four approvals, changes and recalls made by the FDA that are connected to the anesthesia space, as reported by Becker’s so far in 2025.
- The FDA has announced requirements for safety labeling on all opioid pain medications that place renewed emphasis on the risks associated with their long-term use.
- The FDA issued a Class I recall for multiple anesthesia breathing circuit kits due to cracks in the hose that could cause inadequate ventilation.
- Pharmaceutical company Avenacy launched Propofol injectable emulsion, USP, in the U.S. to be used for intravenous general anesthetic and sedation. The drug is approved by the FDA as a generic equivalent to general anesthetic Diprivan.
- Specialty pharmaceutical company PharmaTher Holdings’ drug application for Ketamine was advanced by the FDA.
